--- title: "Sensus Healthcare | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 3.394 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285659333.md" datetime: "2026-05-08T03:40:55.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285659333.md) - [en](https://longbridge.com/en/news/285659333.md) - [zh-HK](https://longbridge.com/zh-HK/news/285659333.md) --- # Sensus Healthcare | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 3.394 M Revenue: As of FY2026 Q1, the actual value is USD 3.394 M, missing the estimate of USD 5.323 M. EPS: As of FY2026 Q1, the actual value is USD -0.16. EBIT: As of FY2026 Q1, the actual value is USD -4.483 M. #### Revenue Sensus Healthcare, Inc. reported revenues of $3.4 million for the three months ended March 31, 2026, a decrease from $8.3 million for the same period in 2025, primarily due to the absence of sales to its historically largest customer and fewer units shipped . Excluding sales to this largest customer, revenue for the three months ended March 31, 2026, increased compared to $2.7 million in the prior year . #### Cost of Sales Cost of sales was $2.4 million for the three months ended March 31, 2026, down from $4.0 million in the prior-year period, mainly due to a lower number of units sold and a shift towards placements under Fair Deal Agreement program and rental arrangements . #### Gross Profit and Margin Gross profit for the first quarter of 2026 was $1.0 million, a decrease from $4.4 million in the prior-year period . The gross margin was 29.2% in the first quarter of 2026, compared to 52.2% in the corresponding period in 2025, driven by product mix including a higher proportion of international shipments and costs associated with new system placements under the Fair Deal Agreement program . #### Operating Expenses General and administrative expense decreased to $2.0 million for Q1 2026 from $2.2 million for Q1 2025, primarily due to lower professional fees . Selling and marketing expense decreased by $0.5 million to $1.7 million for Q1 2026 from $2.2 million for Q1 2025, mainly due to a reduction in tradeshow expenses . Research and development expense decreased by $1.0 million to $1.6 million for Q1 2026 from $2.6 million for Q1 2025, primarily due to reductions in lobbying costs, headcount, and product development for next-generation systems . Total operating expenses were $5.349 million for Q1 2026, compared to $7.000 million for Q1 2025 . #### Loss from Operations Loss from operations was -$4.358 million for Q1 2026, compared to -$2.646 million for Q1 2025 . #### Other Income Other income, primarily interest income, was $0.125 million for Q1 2026, compared to $0.184 million for Q1 2025 . #### Net Loss Net loss was -$2.6 million, or -$0.16 per share, for the three months ended March 31, 2026, which was consistent with the net loss of -$2.6 million, or -$0.16 per share, for the three months ended March 31, 2025 . #### Adjusted EBITDA (Non-GAAP) Adjusted EBITDA for the first quarter of 2026 was -$4.2 million, compared with -$2.5 million for the first quarter of 2025 . #### Cash and Liquidity Sensus Healthcare, Inc. ended the first quarter of 2026 with $18.3 million in cash and cash equivalents, down from $22.1 million as of December 31, 2025 . The company had no outstanding borrowings under its revolving line of credit as of March 31, 2026 . #### Inventories Inventories were $16.5 million as of March 31, 2026, compared to $14.6 million as of December 31, 2025 . Prepaid inventory was $2.5 million as of March 31, 2026, compared to $1.6 million as of December 31, 2025 . #### Operational Highlights Sensus Healthcare, Inc. shipped 14 SRT systems in Q1 2026, comprising 10 direct sales and 4 placements under Fair Deal Agreement program and rental arrangements, compared to 30 systems in the prior-year period (21 direct sales and 9 Fair Deal Agreement program placements) . None of the Q1 2026 direct sales were to the company’s historically largest customer, whereas 15 were in the prior-year period . Dedicated CPT Codes for SRT and IG-SRT became effective January 1, 2026, providing reimbursement certainty for non-melanoma skin cancer treatment, which led to increased inquiry levels, stronger pipeline activity, and greater customer engagement . The company continued expanding its Fair Deal Agreement program, with treatment volumes increasing 8% over the first quarter of 2025, and as of March 31, 2026, there were 18 active sites and 9 sites pending activation . Sensus Healthcare, Inc. also launched Sensus Healthcare Financial Services to support customer acquisition and financing flexibility, and introduced Sensus Link, which provides advanced operating capabilities to the SRT-100™ installed base . #### Outlook / Guidance Sensus Healthcare, Inc. is focusing on five priorities for 2026: education and training, accelerating customer adoption, expanding recurring revenue, broadening commercial reach, and driving the company toward profitability . The new dedicated CPT Codes are expected to significantly improve the quality of the sales pipeline, increase customer engagement, shorten decision-making processes, and support continued diversification of the customer base . The company aims to expand higher-margin recurring revenue streams through initiatives like Sensus Link, which provides enhanced workflow and operating intelligence capabilities . ### Related Stocks - [SRTS.US](https://longbridge.com/en/quote/SRTS.US.md) ## Related News & Research - [11:41 ETOvation Healthcare Shares How Hospitals Can Stay Resilient Amid Legislative Change](https://longbridge.com/en/news/277073443.md) - [Aspire Biopharma Announces 1-for-30 Reverse Stock Split](https://longbridge.com/en/news/286469924.md) - [Cerebras swings IPO focus to tech and AI. But healthcare and industrials still lead](https://longbridge.com/en/news/286448979.md) - [Did Nurix’s (NRIX) EHA Oral BTK Degrader Data Just Reframe Its Oncology Investment Narrative?](https://longbridge.com/en/news/286475954.md) - [Cisco Stock Roars Back — And These Congress Members Have Skin In The Game](https://longbridge.com/en/news/286442223.md)